New pill could help severe heart failure patients avoid hospital
NCT ID NCT07444398
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug vericiguat to standard heart failure treatment can reduce hospital stays and deaths in people with severe, decompensated heart failure. About 130 participants will be randomly assigned to get vericiguat or a placebo, and researchers will track outcomes over three months. The trial is still in early stages, so the main focus is safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vericiguat tablet
What this could lead to
If it works, this could point toward a new add-on treatment to reduce hospitalizations and deaths in people with severe heart failure.
What could go wrong
This is a very early Phase 1 trial with only 130 people, so results may not apply widely. The drug can cause low blood pressure and stomach issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DECOMPENSATED HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Armed Forces Institute of Cardiology. Pakistan
RECRUITINGRawalpindi, Punjab Province, 46000, Pakistan
Contact Phone: •••-•••-•••• Email: •••••@•••••